Safety study of oral ABS-1230 in healthy adults
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests a new oral medication called ABS-1230 in healthy people to see how safe it is and how the body processes it. You would take either the drug or a placebo (no active ingredient) and be monitored closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old
- You need to be generally healthy with no major medical issues
- Your body mass index (BMI) must be between 18 and 32 (you can check this with your height and weight)
- You must agree to use effective birth control and not donate sperm or eggs during the study
- You cannot have HIV, hepatitis B, or hepatitis C
- You must not have a history of cancer (except treated skin cancers) or alcohol/drug problems in the last 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
This study tests a new drug called KS101 to see if it is safe in healthy people. You will receive either a single dose or multiple doses of the drug, and doctors will watch for any side effects.
This trial tests a new medication called ABS-201 for hair loss. It will first see if the medicine is safe in healthy people, then test if it helps those with male or female pattern baldness.
This trial tests a new medicine called AB102 in healthy people to see if it is safe and how the body processes it. It may help researchers understand the right dose for future studies.
This trial tests how a new drug called ABSK-011 is absorbed by the body when taken with a low-fat meal, a high-fat meal, or a stomach acid medicine. Healthy volunteers are needed to help understand these effects.
This early-phase study tests a new oral tablet (YR011) in healthy volunteers to see how safe it is and how the body processes it. It helps find the right dose for future studies.
Hear when a new KCNT1-Related Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.